Aberdeen Group plc increased its stake in shares of Immunic, Inc. (NASDAQ:IMUX – Free Report) by 32.3% during the third quarter, Holdings Channel.com reports. The institutional investor owned 1,090,427 shares of the company’s stock after buying an additional 266,034 shares during the quarter. Aberdeen Group plc owned 0.08% of Immunic worth $10,141,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds have also recently made changes to their positions in the company. Braidwell LP bought a new position in Immunic in the 2nd quarter worth $9,914,000. Bank of America Corp DE increased its position in Immunic by 80,724.2% in the first quarter. Bank of America Corp DE now owns 143,867 shares of the company’s stock worth $160,000 after buying an additional 143,689 shares in the last quarter. OMERS ADMINISTRATION Corp purchased a new stake in Immunic in the first quarter worth about $187,000. Renaissance Technologies LLC bought a new position in shares of Immunic in the first quarter worth about $1,020,000. Finally, Avidity Partners Management LP raised its stake in shares of Immunic by 42.6% in the first quarter. Avidity Partners Management LP now owns 6,699,411 shares of the company’s stock worth $7,436,000 after buying an additional 2,000,000 shares during the period. 51.82% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
IMUX has been the subject of a number of recent research reports. Zacks Research downgraded Immunic from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 10th. Cantor Fitzgerald started coverage on shares of Immunic in a research note on Friday, October 23rd. They set an “overweight” rating on the stock. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price target on shares of Immunic in a report on Wednesday. Wedbush reiterated an “outperform” rating and issued a $45.00 price target on shares of Immunic in a research report on Thursday, September 10th. Finally, Roth Capital reissued a “buy” rating on shares of Immunic in a research note on Tuesday, September 1st. Two investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $32.71.
Immunic Price Performance
IMUX stock opened at $7.52 on Thursday. Immunic, Inc. has a 1-year low of $5.06 and a 1-year high of $17.43. The business has a 50 day simple moving average of $8.38 and a two-hundred day simple moving average of $11.54. The company has a market capitalization of $119.43 million, a price-to-earnings ratio of -1.85 and a beta of 1.48.
Immunic (NASDAQ:IMUX – Get Free Report) last released its quarterly earnings data on Friday, November 13th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.79) by ($0.20). Sell-side analysts anticipate that Immunic, Inc. will post -3.79 EPS for the current fiscal year.
Immunic News Summary
Investors following IMUX have been watching these news items:
- Positive Sentiment: HC Wainwright maintained its Buy rating and $22 price target, while raising its Q4 2026 and FY2027 EPS estimates to smaller expected losses. That offers some support, although the company is still forecast to report losses. MarketBeat analyst estimates
- Neutral Sentiment: A December multiple-sclerosis readout is approaching and could be a significant catalyst for IMUX. The article frames the data as a potential driver of a rally, but the outcome is uncertain and could also disappoint investors. Immunic nears multiple sclerosis readout
- Negative Sentiment: Forecast revisions were not uniformly positive: Brookline Capital Markets lowered its Q4 and FY2026 estimates to larger losses, and HC Wainwright reduced estimates for several later years. Wall Street Zen also cut its rating on Immunic to “Strong Sell,” adding to cautious sentiment. Immunic cut to Strong Sell at Wall Street Zen
About Immunic
Immunic, Inc. is a clinical-stage biopharmaceutical company developing oral small-molecule treatments for chronic inflammatory and autoimmune diseases. The company’s research focuses on therapies intended to address conditions with significant unmet medical needs. Its lead drug candidate, vidofludimus calcium, is being developed for multiple sclerosis. Immunic is also advancing other investigational compounds, including IMU-856, which is being studied for its potential to support intestinal barrier function in gastrointestinal diseases.
Featured Articles
- Five stocks we like better than Immunic
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Want to see what other hedge funds are holding IMUX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunic, Inc. (NASDAQ:IMUX – Free Report).
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.
